Adaptive Biotechnologies is trading 4.7% up now at $28.06, as investors respond to management’s Morgan Stanley fireside chat highlighting progress separating its MRD and Immune Medicine businesses.
- On September 15, shares gained 7.67% to $26.68; coverage specifically linked the jump to that update.
- The broader biotech sector was weaker, suggesting company-specific momentum rather than sector participation.
- The conference appearance was scheduled for 4:50 p.m. EDT.